Clinical trials of receptor protein tyrosine kinase inhabitors in malignant glioma

doi:10.3760/cma.j.issn.1673-422X.2013.11.010

Abstract

Abstract: The occurrence and development of malignant glioma are closely related to abnormal overexpression and activation of receptor tyrosine kinase (RTK) signal transduction pathways. Targeted therapeutic drugs such as RTK inhibitors, RTK downstream signaling pathway inhibitors and multitarget inhibitors can targeting treat malignant glioma at molecular level, some of which have been investigated in clinical trials and achieved good therapeutic effects.

Key words: Glioma, Clinical trial, Receptor protein-tyrosine kinase inhabitor

ZHU Hao, XU Jin-Fang, SHEN Hong. Clinical trials of receptor protein tyrosine kinase inhabitors in malignant glioma[J]. Journal of International Oncology, 2013, 40(11): 833-836.

References

［1］ McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455(7216):1061-1068. ［2］ van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase Ⅱ trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol, 2009, 27(8):1268-1274. ［3］ Raizer JJ, Abrey LE, Lassman AB, et al. A phase Ⅰ trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy and recurrent malignant gliomas and meningiomas. J Neuro Oncol, 2010, 12(1):87-94. ［4］ Raizer JJ, Abrey LE, Lassman AB, et al. A phase Ⅱ trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. J Neuro Oncol, 2010, 12(1):95-103. ［5］ Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase Ⅱ trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. J Neuro Oncol, 2010,12(12):1300-1310. ［6］ Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase Ⅱ trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neuro Oncol, 2010, 98(1):93-99. ［7］ Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys, 2013, 85(5):1206-1211. ［8］ Thiessen B, Stewart C, Tsao M, et al. A phase Ⅰ/Ⅱ trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol, 2010, 65(2):353-361. ［9］ Eskens FA, Mom CH, Planting AS, et al. A phase Ⅰ dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer, 2008, 98(1):80-85. ［10］ Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol, 2009, 5(11):610-620. ［11］ Brave SR, Ratcliffe K, Wilson Z, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther, 2011, 10(5):861-873. ［12］ Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11(1):83-95. ［13］ Batchelor TT, Duda DG, di Tomaso E, et al. Phase Ⅱ study of cediranib, an oral panvascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol, 2010, 28(17):2817-2823. ［14］ Reardon DA, Egorin MJ, Desjardins A, et al. Phase Ⅰ pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, 115(10):2188-2198. ［15］ Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase Ⅰ/Ⅱ study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer, 2010, 46(2):348-354. ［16］ Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol, 2010, 96(3):393-402. ［17］ Raymond E, Brandes AA, Dittrich C, et al. Phase Ⅱ study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol, 2008, 26(28):4659-4665. ［18］ Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase Ⅱ studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer, 2009, 101(12):1995-2004. ［19］ Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res, 2009, 29(12):5171-5184. ［20］ Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase Ⅰ trial for patients with recurrent PTENdeficient glioblastoma. PLoS Med, 2008, 5(1):e8. ［21］ Geoerger B, Kieran MW, Grupp S, et al. Phase Ⅱ trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer, 2012, 48(2):253-262. ［22］ Lassen U, Sorensen M, Gaziel TB, et al. Phase Ⅱ study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res, 2013, 33(4):1657-1660. ［23］ Lustig R, Mikkelsen T, Lesser G, et al. Phase Ⅱ preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol, 2008, 10(6):1004-1009. ［24］ Wick W, Puduvalli VK, Chamberlain MC, et al. Phase Ⅲ study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol, 2010, 28(7):1168-1174. ［25］ Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res, 2009, 69(17):6889-6898. ［26］ Milano V, Piao Y, LaFortune T, et al. Dasatinibinduced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther, 2009, 8(2):394-406. ［27］ Iwamoto FM, Lamborn KR, Robins HI, et al. Phase Ⅱ trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol, 2010, 12(8):855-861. ［28］ Peereboom DM, Ahluwalia MS, Ye X, et al. NABTT 0502: a phase Ⅱ and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Neuro Oncol, 2013, 15(4):490-496. ［29］ Pan E, Yu D, Yue B, et al. A prospective phase Ⅱ single-institution trial of sunitinib for recurrent malignant glioma.J Neurooncol, 2012, 110(1):111-118. ［30］ Kreisl TN, McNeill KA, Sul J, et al. A phase Ⅰ/Ⅱ trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol, 2012, 14(12):1519-1526.

[1]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[2]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[3]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[4]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[5]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[6]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[7]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.
[8]	Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma [J]. Journal of International Oncology, 2021, 48(3): 172-175.
[9]	Li Yuxiang, Wang Xinwen. Interferon-related signaling pathways and clinical application in tumor therapy [J]. Journal of International Oncology, 2020, 47(6): 364-367.
[10]	Zhao Congxuan, Yu Tao. Mining and prediction of glioma-related genes [J]. Journal of International Oncology, 2020, 47(5): 293-296.
[11]	Li Kaichun, Wang Yajie. Current status of clinical researches on metastatic triple negative breast cancer [J]. Journal of International Oncology, 2020, 47(3): 169-173.
[12]	Nan Yang, Zhong Yue. New research advances of long non-coding RNA in glioma [J]. Journal of International Oncology, 2020, 47(2): 98-102.
[13]	Zhang Wen, Song Qibin, Hu Weiguo. Clinical application of multimodal magnetic resonance imaging in glioma [J]. Journal of International Oncology, 2020, 47(11): 686-690.
[14]	Chen Liang, Qin Jun, Lei Junrong, Liu Jun, Wang Lu. miR-1254 inhibits the proliferation and invasion of glioma cells by targeting CSF-1 [J]. Journal of International Oncology, 2020, 47(10): 577-584.
[15]	Zhang Qianhui, Zhang Yang, Su Weipeng, Zhang Song′an, Liu Pan, Zhao Huarong. Expressions of LSD1, MGMT and Ki-67 in high-grade glioma and their influences on prognosis [J]. Journal of International Oncology, 2019, 46(9): 519-525.